Having trouble accessing articles? Reset your cache.

Twynsta telmisartan/amlodipine: Phase III data

In a double-blind Phase III trial in 858 patients with severe hypertension, an 80/10 mg formulation of Twynsta telmisartan/amlodipine met the primary endpoint

Read the full 237 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE